Activated clotting time: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:


==Overview==
==Overview==
The activated clotting time was introduced during the 1970s as a test to monitor the administration and subsequent reversal of unfractionated heparin (UFH) during coronary artery bypass graft surgery.  Currently the test is widely used in the cardiac catheterizaiton laboratory to monitor the adequecy of UFH dosing.  While practice patterns in Europe are such that a large single dose of UFH is administered for a percutaneous coronary intervention (PCI) (150 Units/per Kg), in the United States, lower doses of UFH (35 to 70U/kg depending upon the operator) are administered, and subesquent doses of UFH are titrated based upon the ACT.  In the absence of a glycoprotein 2b3a inhbitor, the target ACT is usually 250 to 300 seconds. If a glycoprotein 2b3a inhibitor has been administered, the target ACT is lower, at 200 to 250 seconds. Despite the aggressive use of ACT monitoring, there is scant data to relate the value to efficacy or bleeding outcomes in the setting of PCI.
The activated clotting time (ACT) was introduced during the 1970s as a test to monitor the administration and subsequent reversal of unfractionated heparin (UFH) during coronary artery bypass graft surgery.  Currently the test is widely used in the cardiac catheterization laboratory to monitor the adequacy of UFH dosing.  The unit of measure is in seconds.
 
==Titration of UFH dosing based upon the ACT==
While practice patterns in Europe are such that a large single dose of UFH is often administered for a percutaneous coronary intervention (PCI) (150 Units/per Kg), in the United States, lower doses of UFH (35 to 70U/kg depending upon the operator) are administered, and subsequent doses of UFH are titrated based upon the ACT.  In the absence of a [[glycoprotein 2b3a inhbitor]], the target ACT is usually 250 to 300 seconds. If a glycoprotein 2b3a inhibitor has been administered, the target ACT is lower, at 200 to 250 seconds.  
 
==Relationship of the ACT to clinical outcomes==
Despite the aggressive use of ACT monitoring, there is scant data to relate the peak ACT to efficacy or bleeding outcomes in the setting of PCI.


{{SIB}}
{{SIB}}

Revision as of 14:59, 15 February 2009

WikiDoc Resources for Activated clotting time

Articles

Most recent articles on Activated clotting time

Most cited articles on Activated clotting time

Review articles on Activated clotting time

Articles on Activated clotting time in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Activated clotting time

Images of Activated clotting time

Photos of Activated clotting time

Podcasts & MP3s on Activated clotting time

Videos on Activated clotting time

Evidence Based Medicine

Cochrane Collaboration on Activated clotting time

Bandolier on Activated clotting time

TRIP on Activated clotting time

Clinical Trials

Ongoing Trials on Activated clotting time at Clinical Trials.gov

Trial results on Activated clotting time

Clinical Trials on Activated clotting time at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Activated clotting time

NICE Guidance on Activated clotting time

NHS PRODIGY Guidance

FDA on Activated clotting time

CDC on Activated clotting time

Books

Books on Activated clotting time

News

Activated clotting time in the news

Be alerted to news on Activated clotting time

News trends on Activated clotting time

Commentary

Blogs on Activated clotting time

Definitions

Definitions of Activated clotting time

Patient Resources / Community

Patient resources on Activated clotting time

Discussion groups on Activated clotting time

Patient Handouts on Activated clotting time

Directions to Hospitals Treating Activated clotting time

Risk calculators and risk factors for Activated clotting time

Healthcare Provider Resources

Symptoms of Activated clotting time

Causes & Risk Factors for Activated clotting time

Diagnostic studies for Activated clotting time

Treatment of Activated clotting time

Continuing Medical Education (CME)

CME Programs on Activated clotting time

International

Activated clotting time en Espanol

Activated clotting time en Francais

Business

Activated clotting time in the Marketplace

Patents on Activated clotting time

Experimental / Informatics

List of terms related to Activated clotting time

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Synonyms and keywords: ACT

Overview

The activated clotting time (ACT) was introduced during the 1970s as a test to monitor the administration and subsequent reversal of unfractionated heparin (UFH) during coronary artery bypass graft surgery. Currently the test is widely used in the cardiac catheterization laboratory to monitor the adequacy of UFH dosing. The unit of measure is in seconds.

Titration of UFH dosing based upon the ACT

While practice patterns in Europe are such that a large single dose of UFH is often administered for a percutaneous coronary intervention (PCI) (150 Units/per Kg), in the United States, lower doses of UFH (35 to 70U/kg depending upon the operator) are administered, and subsequent doses of UFH are titrated based upon the ACT. In the absence of a glycoprotein 2b3a inhbitor, the target ACT is usually 250 to 300 seconds. If a glycoprotein 2b3a inhibitor has been administered, the target ACT is lower, at 200 to 250 seconds.

Relationship of the ACT to clinical outcomes

Despite the aggressive use of ACT monitoring, there is scant data to relate the peak ACT to efficacy or bleeding outcomes in the setting of PCI.

Template:SIB